Pasini F, Pelosi G, Ledermann J A, Cetto G L
Divisione e Cattedra di Oncologia Medica, Università di Verona, Italy.
Int J Cancer Suppl. 1994;8:53-6. doi: 10.1002/ijc.2910570711.
We have used immunocytochemistry to identify tumor cells in bone-marrow aspirates of patients with small-cell lung cancer and we have compared the results with conventional histomorphology. The monoclonal antibodies (MAbs) used were NCC-LU-243 and NCC-LU-246 (cluster 1) and MLuC1 (cluster 6); 108 slides (52 patients) incubated with NCC-LU-246, 106 (51 patients) with NCC-LU-243 and 69 with MLuC1 (36 patients) were evaluated. Bone-marrow biopsies (83) were also obtained from 50 of these patients; 48/108 bone marrow aspirates were positive for cluster-1 antigen and 22/69 were positive for MLuC1. Immunocytochemistry with anti-NCAM MAbs detected bone-marrow localization in 38/83 bone-marrow aspirates compared with 9/83 bone-marrow biopsies, while MLuC1 was positive in 18/60 and bone-marrow biopsies in 6/60. Moreover, bone-marrow aspirates were positive for cluster-1 antigen in 7/17 patients with limited disease at diagnosis. Patients with positive bone-marrow biopsies had significantly shorter survival. No differences were found between patients with positive and those with negative marrow aspirates.
我们运用免疫细胞化学方法鉴定小细胞肺癌患者骨髓穿刺物中的肿瘤细胞,并将结果与传统组织形态学进行比较。所用的单克隆抗体(MAbs)为NCC-LU-243和NCC-LU-246(第1组)以及MLuC1(第6组);对用NCC-LU-246孵育的108张玻片(52例患者)、用NCC-LU-243孵育的106张玻片(51例患者)以及用MLuC1孵育的69张玻片(36例患者)进行了评估。还从其中50例患者获取了骨髓活检标本(83份);108份骨髓穿刺物中有48份第1组抗原呈阳性,69份中有22份MLuC1呈阳性。与83份骨髓活检标本中的9份相比,用抗NCAM单克隆抗体进行免疫细胞化学检测发现38份骨髓穿刺物中有骨髓定位,而MLuC1在60份中的18份呈阳性,骨髓活检标本在60份中的6份呈阳性。此外,在诊断时患有局限性疾病的17例患者中,7例的骨髓穿刺物第1组抗原呈阳性。骨髓活检呈阳性的患者生存期明显较短。骨髓穿刺物呈阳性和呈阴性的患者之间未发现差异。